2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3259 A first-in-class dual FLT3/BRAF inhibitor overcomes RAS-mediated resistance in FLT3-mutant acute myeloid leukemia

Shikhar Sharma, PhD, Anna Skwarska, PhD2, Evangelia Matenoglou3, Sovira Chaudhry4, Catherine Smith, MD5, Donald Small, MD, PhD6, Kira Gritsman, MD, PhD7, Murugan Selvam, PhD8, Marianna Giorgi, BE9, Pamela J. Sung, MD PhD10, Eunice Sue Wang, MD11, Evripidis Gavathiotis, PhD12, Ioannis Mantzaris, MD, MS13, Mendel Goldfinger, MD14, Marina Konopleva, MD, PhD15
1 Albert Einstein College of Medicine, Bronx, New York, United States
2 Albert Einstein College of Medicine, Bronx, New York, United States
3 Albert Einstein College of Medicine, Bronx, New York, United States
4 Albert Einstein College of Medicine, Bronx, New York, United States
5 University of California, San Francisco, California, United States
6 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
7 Albert Einstein College of Medicine, Bronx, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Albert Einstein College of Medicine, Bronx, New York, United States
13 Montefiore Einstein Comprehensive Cancer Center, New York, New York, United States
14 Montefiore Einstein Comprehensive Cancer Center, New York, New York, United States
15 Albert Einstein College of Medicine, Bronx, New York, United States

Introduction: Acute myeloid leukemia (AML) is driven by diverse genetic alterations affecting cell growth and survival pathways, including Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations, which occur in ~30% of AML cases and are associated with aggressive disease and poor prognosis. Targeted therapies against FLT3 have improved treatment options and are incorporated into combination regimens. However, relapse remains common in FLT3-mutant AML due to activation of bypass pathways, particularly the RAS/MAPK pathway. Acquired NRAS/KRAS mutations arising in approximately 20–30% of patients are a major mechanism of resistance to FLT3 inhibitors, reactivating RAS/MAPK signaling and limiting the durability of current therapies. Using a novel structure-based strategy, we developed PHI3, a first-in-class dual FLT3/BRAF inhibitor designed to simultaneously inhibit FLT3 and the RAS/MAPK bypass pathway driving resistance.

Results: In vitro kinase and NanoBRET® target engagement assays demonstrated potent inhibition of wild-type and mutant FLT3 and BRAF by PHI3 at nanomolar concentrations. FLT3-ITD AML cell lines (MOLM13, MOLM14, and MV4-11) were highly sensitive to PHI3 (IC₅₀ <100 nM), while FLT3/RAS-mutant AML cells remained sensitive (IC₅₀ <400 nM). PHI3 inhibited phosphorylation of FLT3, MEK/ERK, STAT5, AKT, and S6 in FLT3-ITD AML cells and MOLM14, MOLM14 NRASG12C, and NRASQ61K isogenic models, whereas gilteritinib failed to suppress MAPK signaling in NRAS-mutant AML models. In competitive outgrowth assays, PHI3 suppressed both parental and RAS-mutant MOLM14 populations, while gilteritinib inhibited only parental cells. PHI3 induced significantly greater apoptosis than gilteritinib in NRAS-mutant AML, as demonstrated by caspase-3/7 activation and Annexin V/PI staining, and outperformed clinically relevant RAF-, MEK-, and RAS-targeted inhibitors, including LY3009120, naporafenib, sorafenib, trametinib, and daraxonrasib. In primary AML samples, PHI3 reduced viability, impaired clonogenic growth, and induced apoptosis, while exhibiting minimal effects on healthy bone marrow CD34⁺ cells.

Genetic BRAF silencing restored gilteritinib sensitivity in NRAS-mutant AML cells, phenocopying the pro-apoptotic activity of PHI3 and providing genetic evidence that BRAF inhibition overcomes RAS-mediated resistance. RNA sequencing further demonstrated suppression of mutant RAS transcriptional programs in PHI3-treated NRAS-mutant AML cells. PHI3 was well tolerated in mice following 14 days of daily dosing up to 200 mg/kg, with no significant changes in body weight, blood counts, or cardiac and hepatic toxicity markers. In FLT3-ITD and FLT3-ITD/NRASG12C xenograft models, PHI3 at a daily dose of 60 mg/kg reduced leukemia burden and significantly prolonged survival, outperforming gilteritinib in NRAS-mutant disease. In MOLM14 tumors, PHI3 and gilteritinib showed comparable efficacy with median survival of 29 days for PHI3 and gilteritinib and 20 days for vehicle, whereas PHI3 outperformed gilteritinib in NRASG12C tumors with median survival of 38, 24, and 20 days for PHI3, gilteritinib, and vehicle, respectively.  Pharmacodynamic analyses confirmed sustained inhibition of MAPK signaling in FLT3-ITD/NRASG12C mutant tumors by PHI3 but not gilteritinib.

Conclusions: Our study demonstrates the efficacy of the first-in-class dual BRAF/FLT3 inhibitor, PHI3, that overcomes RAS-mediated resistance in FLT3-mutant AML by simultaneously suppressing the primary oncogenic driver and the dominant RAF/MAPK bypass pathway. These findings demonstrate dual FLT3/BRAF inhibition as a promising therapeutic strategy for patients with FLT3-mutant AML who relapse through RAS pathway activation.
Shikhar Sharma, PhD: No relevant conflicts of interest to declare.